Statement of Ownership (sc 13g)
08 Febrero 2022 - 3:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities
Exchange Act of 1934
(Amendment No. )*
Ibere
Pharmaceuticals
(Name of Issuer)
Class A
ordinary share, $0.0001 par value per share
(Title of Class of Securities)
G46843 101
(CUSIP Number)
December
31, 2021
(Date of Event Which Requires Filing of this
Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
*The remainder of this cover page shall be filled
out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
|
CUSIP No.
|
|
SCHEDULE 13G
|
|
Page of Pages
|
|
1
|
NAMES
OF REPORTING PERSONS
PIPV
Capital LLC
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b)
¨
|
|
3
|
SEC
USE ONLY
|
|
4
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH:
|
5
|
SOLE
VOTING POWER
0
shares
|
|
6
|
SHARED
VOTING POWER
3,450,000
shares12
|
|
7
|
SOLE
DISPOSITIVE POWER
0
shares
|
|
8
|
SHARED
DISPOSITIVE POWER
3,450,000
shares
|
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,450,000
shares
|
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)
|
¨
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
20.0%3
|
|
12
|
TYPE OF REPORTING PERSON (see Instructions)
OO
|
|
|
|
|
|
|
1
PIPV Capital LLC (the “Sponsor”) is the record holder of the shares of Class B common stock.
2
The Sponsor owns 3,450,000 Class B ordinary shares, par value $0.0001 per share (“Class B Ordinary Share”) of Ibere Pharmaceuticals
(the “Issuer”), which are convertible into Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”)
of the Issuer, as described under the heading “Description of Securities—Common Stock—Founder Shares” in the Issuer’s
prospectus initially filed on February 9, 2021 (File No. 333-252863 and have no expiration date).
3
As of November 12, 2021, there were 13,800,000 Class A Ordinary Shares and 3,450,000 Class B Ordinary Shares issued and outstanding on
Form 10-Q filed on November 12, 2021.
Item 1.
Ibere Pharmaceuticals (the “Issuer”)
|
|
(b)
|
Address of Issuer’s Principal Executive Offices:
|
2005 Market Street, Suite 2030 Philadelphia,
PA 19103
Item 2.
|
|
(a)
|
Name of Person Filing:
|
PIPV Capital LLC
|
|
(b)
|
Address of Principal Business Office or, if none, Residence:
|
2005 Market Street, Suite 2030 Philadelphia,
PA 19103
PIPV Capital LLC is a Delaware limited
liability company.
|
|
(d)
|
Title of Class of Securities:
|
Class A Ordinary Shares, par value $0.0001
per share
There is no CUSIP
number assigned to the Class B Ordinary Shares. CUSIP number G46843 101 has been assigned to the Class A Ordinary Shares of the Issuer,
which are quoted on The New York Stock Exchange under the symbol “IBER.”
|
|
Item 3.
|
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
Not applicable.
|
|
(a)
|
¨
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
|
|
|
|
|
|
(b)
|
¨
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
|
|
|
|
|
|
(c)
|
¨
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
|
|
|
|
|
|
(d)
|
¨
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
|
|
|
|
|
|
|
(e)
|
¨
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
|
|
(f)
|
¨
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
|
|
(g)
|
¨
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
|
|
(h)
|
¨
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
|
|
|
|
|
(i)
|
¨
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
|
|
|
|
|
|
(j)
|
¨
|
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
|
|
|
|
|
|
|
|
(k)
|
¨
|
Group, in accordance with §240.13d-1(b)(1)(ii)(K).
|
|
|
|
|
|
|
|
|
|
If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
please specify the type of institution: _____________________________________________________
|
Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: 3,450,000 shares
(b) Percent of class: 20.0%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the
vote: 0 shares
(ii) Shared power to vote or to direct
the vote: 3,450,000 shares
(iii) Sole power to dispose or to direct
the disposition: 0 shares
(iv) Shared power to dispose or to direct
the disposition: 3,450,000 shares
Each manager of PIPV
Capital LLC has one vote, and the approval of two of the three members of the board of managers is required to approve an action of
the Sponsor. Under the so-called “rule of three,” if voting and dispositive decisions regarding an entity’s
securities are made by two or more individuals, and a voting and dispositive decision requires the approval of a majority of those
individuals, then none of the individuals is deemed a beneficial owner of the entity’s securities. This is the situation with
regard to the Sponsor. Based upon the foregoing analysis, no individual manager of the Sponsor exercises voting or dispositive
control over any of the securities held by the Sponsor even those in which he or she directly holds a pecuniary interest.
Accordingly, none of them will be deemed to have or share beneficial ownership of such shares and, for the avoidance of doubt,
expressly disclaims any such beneficial interest to the extent of any pecuniary interest he may have therein, directly or
indirectly.
|
|
Item 5.
|
Ownership of 5 Percent or Less of a Class
|
If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities,
check the following ¨
|
|
Item 6.
|
Ownership of More than 5 Percent on Behalf of Another Person
|
Not Applicable.
|
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
|
Not Applicable.
|
|
Item 8.
|
Identification and Classification of Members of the Group
|
Not Applicable.
|
|
Item 9.
|
Notice of Dissolution of Group
|
Not Applicable.
Not Applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 8, 2022
|
|
PIPV
CAPITAL LLC
|
|
|
|
|
|
By:
|
/s/ Osagie Imasogie
|
|
|
Name:
|
Osagie Imasogie
|
|
|
Title:
|
President
|
Ibere Pharmaceuticals (NYSE:IBER)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Ibere Pharmaceuticals (NYSE:IBER)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
